Nouveau Life Financials
| NOUV Stock | USD 0.0001 0.0001 50.00% |
Nouveau |
Please note, the imprecision that can be found in Nouveau Life's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Nouveau Life Pharmaceuticals. Check Nouveau Life's Beneish M Score to see the likelihood of Nouveau Life's management manipulating its earnings.
Nouveau Life Stock Summary
Nouveau Life competes with Definitive Healthcare, Premier, Omnicell, Goodrx Holdings, and Mitesco. Nouveau Life Pharmaceuticals, Inc., a development stage company, engages in the development of nutraceuticals products. Nouveau Life Pharmaceuticals, Inc. operates as a subsidiary of EMG Marketing Solutions, Inc. Nouveau Life is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US66979K1034 |
| Business Address | 401 East Las |
| Sector | Financial Services |
| Industry | Shell Companies |
| Benchmark | Dow Jones Industrial |
| Website | www.nlpnaturals.com |
| Phone | 954 903 2993 |
| Currency | USD - US Dollar |
Nouveau Life Key Financial Ratios
There are many critical financial ratios that Nouveau Life's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Nouveau Life Pharmac reports annually and quarterly.| Return On Equity | -2.2 | |||
| Return On Asset | -0.2 | |||
| Beta | -4.22 |
Nouveau Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nouveau Life's current stock value. Our valuation model uses many indicators to compare Nouveau Life value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nouveau Life competition to find correlations between indicators driving Nouveau Life's intrinsic value. More Info.Nouveau Life Pharmaceuticals is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Nouveau Life's earnings, one of the primary drivers of an investment's value.Nouveau Life Pharmac Systematic Risk
Nouveau Life's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Nouveau Life volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Nouveau Life Pharmac correlated with the market. If Beta is less than 0 Nouveau Life generally moves in the opposite direction as compared to the market. If Nouveau Life Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Nouveau Life Pharmac is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Nouveau Life is generally in the same direction as the market. If Beta > 1 Nouveau Life moves generally in the same direction as, but more than the movement of the benchmark.
Nouveau Life March 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Nouveau Life help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Nouveau Life Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Nouveau Life Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Nouveau Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Nouveau Life's daily price indicators and compare them against related drivers.
| Downside Deviation | 54.01 | |||
| Information Ratio | 0.1457 | |||
| Maximum Drawdown | 150.0 | |||
| Value At Risk | (50.00) | |||
| Potential Upside | 100.0 |
Additional Tools for Nouveau Pink Sheet Analysis
When running Nouveau Life's price analysis, check to measure Nouveau Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nouveau Life is operating at the current time. Most of Nouveau Life's value examination focuses on studying past and present price action to predict the probability of Nouveau Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nouveau Life's price. Additionally, you may evaluate how the addition of Nouveau Life to your portfolios can decrease your overall portfolio volatility.